[1]陈致雯,石艳红,李盼.舒腹汤加减联合抗生素治疗小儿肠系膜淋巴结炎疗效及对患儿血清炎症因子的影响[J].陕西中医,2025,46(9):1214-1217.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.012]
　CHEN Zhiwen,SHI Yanhong,LI Pan.Efficacy of modified Shufu decoction combined with antibiotics on mesenteric lymphadenitis in children and its influence on serum inflammatory factors[J].,2025,46(9):1214-1217.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.012]
点击复制

舒腹汤加减联合抗生素治疗小儿肠系膜淋巴结炎疗效及对患儿血清炎症因子的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年9期
页码:
1214-1217
栏目:
临床研究
出版日期:
2025-09-05

文章信息/Info

Title:
Efficacy of modified Shufu decoction combined with antibiotics on mesenteric lymphadenitis in children and its influence on serum inflammatory factors
作者:
陈致雯; 石艳红; 李盼
（广州医科大学附属中医医院儿科，广东 广州 510130）
Author(s):
CHEN Zhiwen; SHI Yanhong; LI Pan
（Pediatric Department of Guangzhou Medical University Affiliated Traditional Chinese Medicine Hospital，Guangzhou 510130，China）
关键词:
肠系膜淋巴结炎; 舒腹汤加减; 抗生素; IL-6; 炎症因子; 中医证候积分
Keywords:
Mesenteric lymphadenitis; Modified Shufu decoction; Antibiotics; Interleukin-6; Inflammatory factors; TCM syndrome score
分类号:
R 725.7
DOI:
DOI:10.3969/j.issn.1000-7369.2025.09.012
文献标志码:
A
摘要:
目的：探究舒腹汤加减联合抗生素治疗小儿肠系膜淋巴结炎（ML）的疗效，并观察对患儿血清炎症因子的影响。方法：选取84例ML患儿为研究对象。按照随机数字表法将其分为研究组与对照组，各42例。对照组予以抗生素治疗，研究组基于对照组加用舒腹汤加减治疗，均治疗1个月。评价两组临床疗效及用药安全性，比较组间中医证候积分、肠系膜淋巴结影像检查结果，并分析血清白介素（IL）-8、IL-6与IL-17的水平变化情况。结果：观察组总有效率95.24%，高于对照组80.95%（P＜0.05）；观察组腹痛、腹胀、呕吐等证候消失时间均低于对照组，且在治疗1个月后各项证候积分均低于对照组（P＜0.05）；两组治疗1个月后肠系膜淋巴结纵横径与血清IL-8、IL-6、IL-17水平均低于治疗前，且观察组均低于对照组（P＜0.05）；两组不良反应发生率均低于10%，差异无统计学意义（P＞0.05）。结论：基于抗生素联合舒腹汤加减治疗小儿ML，可有效缓解腹痛等病症，缩小肠系膜淋巴结，下调炎症因子水平，疗法安全且效果优于单纯西药治疗。
Abstract:
Objective:To explore the efficacy of modified Shufu decoction combined with antibiotics in the treatment of mesenteric lymphadenitis (ML) in children,and to observe the influence on serum inflammatory factors.Methods:84 children with ML were divided into study group and control group,with 42 cases in each group.The control group was treated with antibiotics,while the study group was added with modified Shufu decoction based on the control group.Both groups were treated for 1 months.The clinical efficacy and medication safety in the two groups were evaluated.The TCM syndromes scores and mesenteric lymph node imaging results were compared between groups,and the levels of serum interleukin (IL)-8,IL-6 and IL-17 were analyzed.Results:The total effective rate in observation group was 95.24%,which was higher than 80.95% in control group (P<0.05).The disappearance durations of syndromes such as abdominal pain,abdominal distension and vomiting in observation group were shorter than those in control group,and the scores of various syndromes after 1 months of treatment were lower than those in control group (P<0.05).After 1 months of treatment,the longitudinal and transverse diameters of mesenteric lymph nodes and levels of serum IL-8,IL-6 and IL-17 in both groups were lower compared with those before treatment,and the above indicators in observation group were lower compared to control group (P<0.05).The incidence rates of adverse reactions in both groups were less than 10% (P>0.05).Conclusion:Combination of modified Shufu decoction based on antibiotics in the treatment of ML in children can effectively relieve the abdominal pain and other syndromes,shrink the mesenteric lymph nodes,and down-regulate the levels of inflammatory factors.The therapy is safe and its effect is better than that of western medicine alone.

参考文献/References:

[1]党玉萍.小儿急性肠系膜淋巴结炎102例临床特征分析[J].中国药物与临床,2020,20(8):1360-1361.
[2]葛丹阳,李文.柴元方治疗儿童气滞血瘀型肠系膜淋巴结炎的临床研究[J].中国中医基础医学杂志,2024,30(5):871-874.
[3]石得荣,李凤梅,李燕,等.小儿急性肠系膜淋巴结炎采用高频超声诊断及应用头孢他啶治疗的价值研究[J].生命科学仪器,2022,20(z1):249.
[4]常温来,索恩勇,宋超,等.加减和中散联合头孢克洛咀嚼片治疗肠系膜淋巴结炎的疗效观察及对小儿消化功能的影响[J].中国中西医结合消化杂志,2020,28(6):449-453.
[5]王莹,张慧敏.张慧敏基于“肝脾同调”辨治小儿肠系膜淋巴结炎[J].中医临床研究,2023,15(13):117-121.
[6]吴瑞萍,胡亚美,江戴芳.诸福棠实用儿科学[M].9版.北京:人民卫生出版社,2022:1362.
[7]张奇文.实用中医儿科学[M].4版.北京.中国中医药出版社,2019:1802.
[8]国家食品药品监督管理局.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:151-155.
[9]国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994:79.
[10]张方正.高频彩色多普勒超声诊断鉴别小儿肠系膜淋巴结炎和急性阑尾炎准确率分析[J].中国药物与临床,2020,20(18):3013-3014.
[11]张小林,周洪彬,何慧敏,等.基于肠道微生态探讨小儿肠系膜淋巴结炎从脾论治机理[J].广州中医药大学学报,2023,40(4):1025-1029.
[12]鲁姿岐,姬艺匀,曾肖.桂枝汤加减联合抗生素治疗小儿肠系膜淋巴结炎临床观察[J].湖北中医药大学学报,2024,26(5):25-28.
[13]莫容如,吴家煜,郭誉丹,等.罗氏三香包联合西药治疗小儿肠系膜淋巴结炎的随机对照研究[J].山东中医杂志,2024,43(12):1407-1413.
[14]李文,车立娟,张梦思.基于数据挖掘方法研究中医药治疗小儿肠系膜淋巴结炎的药证规律[J].吉林中医药,2021,41(1):111-114.
[15]陈钊扬,何德根,张琳,等.双柏散外敷结合电磁波照射治疗肠系膜淋巴结炎疗效及对患儿临床症状、炎症因子的影响[J].陕西中医,2021,42(2):209-212.
[16]张洪涛,李凤梅,石得荣,等.高频超声对小儿急性肠系膜淋巴结炎诊断价值及准确性分析[J].生命科学仪器,2022,20(z1):40-43.
[17]MIDDLETON L W,SHEN Z,VARMA S,et al.Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis[J].JCI Insight,2019,5(12):e129749.
[18]黄晓丽,王平,葛建新,等.miR-155对溃疡性结肠炎患者外周血Th17细胞分化及功能的影响[J].中国临床研究,2019,32(12):1707-1710.
[19]李姣,文颖娟,彭高强,等.基于肠黏膜屏障探讨炎症性肠病从脾论治的相关研究[J].西部中医药,2024,37(1):112-119.
[20]杨玉玺,李雪梅,吉黎,等.佛手苷内酯下调miR-503表达抑制高糖诱导的肾小管上皮细胞炎性因子表达和细胞凋亡[J].医学分子生物学杂志,2023,20(2):148-153.
[21]蒙诺,杨慧莹,陈金凤,等.和厚朴酚减轻高甘油三酯血症急性胰腺炎大鼠模型的氧化应激:基于激活SIRT3-MnSOD2通路[J].南方医科大学学报,2023,43(3):405-411.
[22]李彬,甘德堃,王璐璐.和厚朴酚通过Notch信号通路抑制慢性阻塞性肺疾病小鼠免疫失衡并提供肺保护作用[J].中国比较医学杂志,2022,32(4):86-93.
[23]李明,李琦,罗佳晶,等.厚朴酚调节MAPK/NF-κB/NLRP3信号通路对动脉粥样硬化大鼠主动脉炎性损伤的影响[J].中医药导报,2023,29(3):49-53.
[24]闫雅婕,王亚亚,梁轩,等.茵陈化学成分、药理作用及在肝胆疾病中的临床应用研究进展[J].中华中医药学刊,2024,42(11):237-248.
[25]熊素琴,刘诗韵,刘艺莹.基于网络药理学探讨布渣叶的抗炎机制[J].广东化工,2024,51(12):163-165.

相似文献/References:

[1]李 果,王秀超,陈 琼△,等.小儿肠系膜淋巴结炎诊断及中医治疗研究进展[J].陕西中医,2019,(9):1318.

备注/Memo

备注/Memo:
广东省中医药局科研项目（20222183)
更新日期/Last Update: 2025-09-08